Exact Sciences (EXAS) Misses Q1 EPS by 21c, Updates Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. MIRM
2. SPY
3. META
4. MSFT
5. PLTR
6. JNJ
7. HUM
8. CSCO
9. KTOS
10. NVDA

Go back to Exact Sciences (EXAS) Misses Q1 EPS by 21c, Updates Guidance

Exact Sciences Announces First-Quarter 2025 Results

May 1, 2025 4:05 PM EDT

First quarter highlights

Delivered total first quarter revenue of $707 million, an increase of 11% on a reported and core revenue basis, including Screening revenue of $540 million and Precision Oncology revenue of $167 million Raised full-year 2025 revenue and adjusted EBITDA guidance midpoints by $40 million and $15 million, respectively Launched the Cologuard Plus test, the company's next-generation colon cancer screening test Presented data in the Journal of Surgical Oncology demonstrating the clinical strength of the Oncodetect test, the companys molecular residual disease (MRD) and recurrence monitoring test

MADISON, Wis.--(BUSINESS WIRE)-- Exact... More